Evaluation of clinical efficacy and safety of the Vamana karma followed by Takradhara and Rasaushadhi rasayana chikitsa in Kitibha (psoriasis)

Central council for Research in Ayurvedic sciences CCRAS0 个研究点目标入组 110 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 3 期
状态: 招募中
发起方
入组人数: 110

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1.Patients of either sex with age between 18 and 60 years
•2.Known cases of psoriasis, without psoriatic arthropathy,
•Exhibiting psoriatic triad â??
•I.Bright pink or red lesions with pronounced edges, covered with silvery white scales, the scales can be easily separated from the lesion
•II.Under the scales there appears a pinkish moist tender skin
•III.With the scarping of the moist skin there appear tiny blood droplets (Auspitzâ??s sign)
•3.Patients suffering from psoriasis with less than 50 % of the body surface involvement
•4.Patients having less than 10 years duration of disease
•5.Positive histopathological finding (Skin-biopsy - optional)

排除标准

•1.Age below 18 years and above 60 years 2.Patients with other forms of Psoriasis like Guttate or Pustular or Erythrodermic or inverse.
•3.Patients suffering from very severe psoriasis with more than 50% of the body surface involvement
•4.Patients having chronic disease i.e. more than 10 years duration
•5.Patients who are not ready for IPD admission or Vamana Karma or follow up as specified
•6.Patients with Psoriatic arthropathy
•7.Patients with poorly controlled Hypertension ( more than 160/100 mmHg)
•8.Patients with poorly controlled Diabetes Mellitus having Hb A1C of greater than 7.5%
•9.Patients on medication with corticosteroids, phototherapy, biologics, antidepressants any other drugs that may have an influence on the outcome of the study.
•10.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•11.Symptomatic patient with clinical evidence of Heart failure.
•12.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) more than 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine more than 1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study.
•13.Alcoholics and/or drug abusers
•14.H/o hypersensitivity to any of the trial drugs or their ingredients
•15.Pregnant/lactating woman.
•16.Patients who have completed participation in any other clinical trial during the past six months.
•17.Other conditions which are of contraindications for Vamana karma
•18.Any other condition which the Investigator thinks may jeopardize the study.

研究者

发起方

Central council for Research in Ayurvedic sciences CCRAS

相似试验

进行中（未招募）

1 期

A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.MedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertension

EUCTR2020-004891-16-LVInstitut de Recherches Internationales Servier968

招募中

不适用

Evaluation of the clinical efficacy and safety of fluticasone propionate/ formoterol fumarate combination (FFC) for the treatment of bronchial asthma-with and without use of an inhalation deviceBronchial Asthma

JPRN-UMIN000015602Kinki university Department of respiratory medicine and allergology50

进行中（未招募）

1 期

EUCTR2020-004891-16-CZInstitut de Recherches Internationales Servier968

进行中（未招募）

1 期

EUCTR2020-004891-16-PLInstitut de Recherches Internationales Servier968

进行中（未招募）

1 期

EUCTR2020-004891-16-HUInstitut de Recherches Internationales Servier968